Yes, I would like to be contacted by a representative to learn more about Bloomberg's solutions and services. By submitting this information, I agree to the privacy policy and to learn more about ...
Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
The high sensitivity of MRI in the depiction of plaques in the brain and spinal cord has made this technique the most important paraclinical tool for the diagnosis of multiple sclerosis (MS). MRI ...
Jan. 14, 2025 A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results